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Background: Large population studies have revealed that increased von Willebrand Factor (VWF) levels
are associated with an increased risk of ischemic stroke. In previous studies VWF was associated with
atherosclerosis in healthy individuals. However, it is yet unknown what the association is between
atherosclerosis and VWF levels in patients with ischemic stroke.
Objectives: The aim of our study was to determine the association of atherosclerosis, measured with
recent developed techniques, and VWF levels in a large, well characterized, cohort of ischemic stroke
patients and to determine the prognostic value.
Methods: We included 925 consecutive patients with transient ischemic attack (TIA) or ischemic stroke.
Calciﬁcation volumes (mm3) were scored in the aortic arch and both carotid arteries using multidetector
computed tomography (CT) angiography. VWF antigen (VWF:Ag) levels were measured using ELISA.
Results: Mean VWF:Ag levels were signiﬁcantly higher in the presence of calciﬁcation in either the aortic
arch (1.47 vs. 1.37 IU/ml [P ¼ 0.039]) or the carotid arteries (1.49 vs. 1.34 IU/ml [P ¼ 0.001]). Patients with
a large artery atherosclerosis ischemic stroke had signiﬁcantly higher VWF:Ag levels then the other
TOAST subtypes (P < 0.0001). High VWF:Ag levels were associated with an unfavorable outcome
(modiﬁed Rankin Scale >2 vs. 2; 1.64 vs. 1.41 IU/ml, [P < 0.0001]).
Conclusion: Our study showed a strong association between the extent of atherosclerosis in both the
aortic arch and the carotid arteries and VWF levels in patients with TIA or ischemic stroke. Higher VWF
levels are found in large artery atherosclerosis and are associated with a poor outcome.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Von Willebrand Factor (VWF) plays a crucial role in platelet
adhesion and aggregation, the initial steps in thrombus formation.
VWF is a multimeric plasma protein that is produced by endothelial
cells and megakaryocytes [1]. Since VWF plasma levels increase as
the result of endothelial damage, VWF levels can be used as a
marker of endothelial dysfunction [2].
Previous studies have shown a positive association between
levels of VWF and risk of coronary heart disease and stroke [3e6].f Hematology, Room Na-820,
l.: þ3110 70 31672; fax: þ31
eebeek).
nd Ltd. All rights reserved.In ischemic stroke, a particular association of VWF levels with
etiologic subtypes, such as large artery atherosclerosis and car-
dioembolic stroke, was found [7]. Despite the fact that prospective
studies have identiﬁed VWF levels as a predictor of ischemic stroke
[8e10], the mechanism by which increased VWF levels are related
to stroke is still unclear.
We have previously shown that genetic variation strongly de-
termines VWF levels, however these genetic variations are not or
minimally associated with ischemic stroke risk [11,12]. Therefore it
has been suggested that the VWF levels may predominantly be
determined by endothelial dysfunction and atherosclerosis [13].
Endothelial dysfunction is the ﬁrst phase in the development of
atherosclerotic plaques. Because endothelial activation is related to
atherosclerosis and an association of VWF with ischemic stroke has
been found, atherosclerosis may be a determinant of VWF levels
[14]. Previous studies have shown a signiﬁcant association between
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media thickness, and increased VWF levels in healthy individuals
[15,16].
In recent years, new techniques have been developed to study
the extent of atherosclerosis more precisely. Calciﬁcation volume is
an important indicator of atherosclerosis severity and may have a
strong association with VWF levels [17e19].
We hypothesized that a higher degree of calciﬁcation volume,
measured both in the aortic arch and carotid arteries, is associated
with higher levels of VWF in patients with ischemic stroke, which
may provide more insight in the relationship between VWF levels
and ischemic stroke risk and the prognostic value of VWF.
2. Materials and methods
2.1. Study population
We studied 925 consecutive patients with TIA or ischemic
stroke from the Erasmus Stroke Study, an ongoing registry of pa-
tients with cerebrovascular diseases treated at our hospital, from
December 2005 until December 2010 of whom plasma, DNA and a
CT angiography was available [20]. TIA was deﬁned as a focal
neurological deﬁcit of presumed vascular origin lasting less than
24 h, with imaging studies showing no abnormalities. Ischemic
stroke was deﬁned as a focal neurological deﬁcit of presumed
vascular origin lasting 24 h, with brain imaging studies showing
no abnormalities or typical signs of infarction. Patients were clas-
siﬁed according to the Trial of Org 10172 in Acute Stroke Treatment
(TOAST) criteria [21] and additionally to a phenotypic classiﬁcation
which is a variant of the A-S-C-O score [22]. This score is charac-
terized by 9 categories: deﬁnite lacunar stroke, deﬁnite athero-
thrombotic stroke, probable atherothrombotic stroke, deﬁnite
cardiac cause, possible cardiac cause, deﬁnite hematologic cause,
possible hematologic cause, other cause of stroke and unknown
cause of stroke. Deﬁnitions are described in the supplemental
information. Patients who have multiple causes of stroke did not
ﬁt into one of the categories and are therefore excluded from the
analysis (N ¼ 125). Hypertension and hypercholesterolemia were
deﬁned as the use of antihypertensive or cholesterol lowering
drugs, respectively, before the inclusion event. Diabetes mellitus
was deﬁned as the use of oral and/or parenteral antidiabetic drugs
before the event. Smoking status (smoking versus non-smoking)
was assessed at the time of the event. Patients were considered
to have a history of ischemic heart disease when they had a
documented myocardial infarction, angina pectoris or cardiac
revascularization therapy. Peripheral arterial disease was deﬁned
as a history of intermittent claudication or peripheral vascular
surgery or amputation due to lower limb ischemia. A history of
cardiovascular disease indicates a history of ischemic heart disease
and/or peripheral arterial disease and/or atrial ﬁbrillation and/or
TIA or ischemic stroke. The National Institutes of Health Stroke
Scale (NIHSS) [23] was assessed at admission from the stroke unit
or outpatient clinic. The functional outcomewas assessed using the
modiﬁed Rankin scale (mRS) [24] at discharge and was dichoto-
mized as favorable (2) or unfavorable (>2) outcome.
All participants provided written informed consent. The study
was approved by the Medical Ethics Committee of the Erasmus
University Medical Center.
2.2. MDCTA angiography
A multidetector CT angiography (MDCTA) was performed
routinely according to a standard protocol. MDCTA was performed
at a median of 5 days (interquartile range 2e14 days) after onset of
symptoms. Image acquisition was performed using a 16, 64 or 128slice multidetector CT system (Sensation 16, Sensation 64, Deﬁni-
tion, Deﬁnition ASþ or Deﬁnition ﬂash, Siemens Medical Solutions,
Erlangen, Germany) using a standardized optimized contrast-
enhanced protocol (120 kVp, 180e200 mAs, collimation
16  0.75 mm; 32  2  0.6 mm; 64  2  0.6 mm, pitch <1). The
scan range extended from the ascending aorta to the intracranial
circulation. All patients received 80 ml of contrast agent (320 mg/
mL iodixanol, Visipaque, Amersham Health, Little Chalfont, UK),
followed by 45 ml saline bolus chaser, both at an injection rate of 4
or 5 ml/s. Real-time bolus tracking at the level of the ascending
aorta was used to synchronize passage of contrast agent and data
acquisition. Image reconstructions were made with ﬁeld of view of
120 mm, matrix size 512  512, slice thickness 0.75 or 1.0 mm,
increment 0.4e0.6 mm and with an intermediate reconstruction
algorithm. All MDCTA studies were evaluated by trained readers
blinded for clinical data. Dedicated commercially available software
(Syngo CalciumScoring, Siemens) was used to quantify calciﬁca-
tions at the aortic arch and the carotid arteries; expressed as
calciﬁcation volume in mm3. The aortic arch was deﬁned as the
origin of the aortic arch to the ﬁrst 1 cm of the common carotid
arteries, the vertebral arteries and the subclavian arteries beyond
the origin of the vertebral arteries. Both carotid arteries were
scored within 3 cm proximal and distal of the bifurcation and
calciﬁcation volume of both carotid arteries was added. A threshold
of 600 Hounsﬁeld units (HU) was used to differentiate calciﬁcations
from contrast material in the lumen. A detailed description of the
measurement is provided elsewhere [17,25].
Reasons for not performing MDCTA were poor renal function,
signiﬁcant comorbidity with resultant very short life expectancy
and very severe stroke with likely fatal outcome. Patients with a
time interval between event and MDCTA of more than 180 days
were excluded (n ¼ 20). Because of poor image quality of both the
aortic arch and the carotid arteries caused by artifacts, 17 scans
were not gradable. In 7 patients the aortic arch and in 10 patients
the carotid arteries could not be analyzed due to dissection of the
carotid artery, presence of artifacts or stents.
2.3. Blood samples, VWF measurement and blood group assessment
Blood sampling was performed at a median of six days (inter-
quartile range 3e14 days) after onset of symptoms. There was no
signiﬁcant correlation between VWF levels and time from event till
blood sampling (b 0,0001 IU/ml per day; P ¼ 0.33).
Citrated blood was centrifuged at 1700 g for 15 min at room
temperature, and stored at 80 C within 2 h from collection. DNA
was isolated from blood usingMagNA Pure (Roche Diagnostics) and
stored at 80 C. VWF antigen (VWF:Ag) levels were determined
with an in-house ELISA, using rabbit anti-human VWF antibodies
(DakoCytomation, Glostrop, Denmark) for catching and tagging.
Reference standard plasma, calibrated against the international
standard (Cryocheck Reference, Kordia, Leiden, the Netherlands),
was used as a calibrator. The intra-assay coefﬁcient of variationwas
3.2%. Blood groups were assessed with a standard test of blood
group antibodies in 572 patients. In the remaining 353 patients, we
genotyped rs687289, which can be used to discriminate blood
group O from non-O status, using custom TaqMan Genotyping
Assays (Applied Biosystems, Foster City, CA, USA) [26]. Genotyping
was successful in 99% of all patients.
2.4. Statistical analysis
Levels of VWF:Ag and the calciﬁcation volumes in the aortic arch
and carotid arteries were normalized by logarithmic trans-
formation. The data are presented as geometric means and 95%
conﬁdence interval (CI). Correlation between two groups was
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rotid calciﬁcation volume were divided into four subgroups. The
ﬁrst group consists of all patients with a calciﬁcation volume of
0 mm3, the remaining patients were divided into tertiles. VWF:Ag
levels were divided into two categories: low level below the me-
dian (1.43 IU/ml) and high level above the median (>1.43 IU/ml).
Groups were compared using independent T-tests or ANOVA with
Bonferroni correction. Linear regression analysis was used to
analyze the relationship between calciﬁcation volume with
VWF:Ag levels. All analyses were adjusted for potential con-
founders: age, sex, ABO blood group, smoking, hypertension, hy-
percholesterolemia, diabetes mellitus and a history of
cardiovascular disease. Only confounders that were signiﬁcantly
associated with VWF:Ag levels were used in the multivariate ana-
lyses. All analyses were performed using SPSS version 20.0 (IBM,
Somers, NY, USA). A P value <0.05 was considered to indicate sta-
tistical signiﬁcance.
3. Results
Baseline characteristics of the 925 patients in this study are
shown in Table 1. Mean age was 62  13.6 years and 47% were fe-
males. As expected in our cohort of patients with TIA or ischemic
stroke, they frequently suffered from hypertension, hypercholes-
terolemia and the majority of patients smoked. The geometric
mean of the VWF:Ag levels in our patients was 1.43 IU/ml (95% CI
0.63e3.24). Patients with ischemic stroke had signiﬁcantly higher
levels of VWF than patients with TIA (1.50 vs. 1.35 IU/ml;
P < 0.0001). Patients with blood group O had signiﬁcantly lower
levels of VWF:Ag compared with patients with non-O blood groups
(1.24 vs 1.62 IU/ml, p < 0.0001). 113 patients had a time interval
between event and MDCTA of more than one month. The results of
the study did not change, when excluding those patients.
3.1. Calciﬁcation volume of the aortic arch and VWF:Ag levels
The geometric mean calciﬁcation volume of the aortic arch of
the total group was 17.59 mm3 (95% CI 0e3374.8 mm3). PatientsTable 1
Baseline characteristics of the study population.
Total cohort
N ¼ 925
Patients in whom
No calciﬁcation
N ¼ 256
Age, years 62.0 (13.6) 49.0 (11.5)
Female sex 443 (46.8) 137 (53.5)
Smoking 283 (30.6) 82 (32.0)
Body mass index (kg/m2) 27.3 (13.5) 27.9 (5.8)
Hypertension 488 (52.8) 76 (29.7)
Hypercholesterolemia 311 (33.6) 43 (16.8)
Diabetes mellitus 128 (13.8) 21 (8.2)
History of CVD 367 (39.7) 54 (21.1)
Bloodgroup
O 416 (45) 115 (44.9)
Non-O 504 (54.5) 141 (55.1)
Diagnosis
TIA 428 (46.3) 130 (50.8)
Stroke 497 (53.7) 126 (49.2)
TOAST classiﬁcation
Large artery atherosclerosis 154 (16.6) 16 (6.3)
Cardioembolism 113 (12.2) 29 (11.3)
Small vessel occlusion 183 (19.8) 51 (19.9)
Other determined etiology 50 (5.4) 25 (9.8)
Undetermined etiology 425 (45.9) 135 (52.7)
Data are presented as N(%), unless for age and body mass index, where mean (SD) are s
CVD indicates cardiovascular disease.with calciﬁcations in the aortic arch (n ¼ 593) had signiﬁcantly
higher VWF:Ag levels compared with patients without calciﬁca-
tions in the aortic arch (n ¼ 325; 1.47 vs. 1.37 IU/ml, P ¼ 0.039).
VWF:Ag levels increased linearly with increasing groups of the
aortic calciﬁcation volume (P for trend 0.003; Fig. 1a). After
multivariate adjustment, age and blood group were signiﬁcantly
associated with levels of VWF:Ag (P < 0.0001; P < 0.0001;
respectively). Patients with blood group O, with mean VWF:Ag
levels of 1.24 IU/ml, had similar aortic calciﬁcation volume
compared with patients with blood group non-O, who had a mean
VWF:Ag level of 1.62 IU/ml (17.2 vs. 18.0 mm3, P ¼ 0.80). The as-
sociation between the calciﬁcation volume and VWF:Ag levels was
seen both in blood group O and non-O and this was not statistically
signiﬁcant different (P for indication ¼ 0.49).
3.2. Calciﬁcation volume of the carotid arteries and VWF:Ag levels
The geometric mean of the carotid calciﬁcation volume of the
total group was 5.7 mm3 (95% CI 0.0e396.9 mm3). Patients with
calciﬁcations (n ¼ 529) had signiﬁcantly higher levels of VWF:Ag
compared with those without calciﬁcations (n ¼ 386; 1.49 vs
1.34 IU/ml, P ¼ 0.001).
VWF:Ag levels increased linearly in increasing groups of the
calciﬁcation volume (P for trend <0.0001; Fig. 1b). Age and blood
group were signiﬁcantly associated with levels of VWF:Ag after
multivariate analysis (P < 0.0001; P < 0.0001, respectively). Pa-
tients with blood group O, with a mean VWF:Ag levels of 1.24 IU/
ml, had a similar carotid calciﬁcation volume compared with pa-
tients with blood group non-O, with a mean VWF:Ag level of
1.61 IU/ml (6.4 vs. 5.3 mm3, P ¼ 0.25).
Calciﬁcation volume of the aortic arch and of the carotid arteries
were highly correlated (R ¼ 0.69; P < 0.0001). Patients with calci-
ﬁcations in both arteries were older (67 vs. 49 years, P < 0.0001)
and had more cardiovascular risk factors than those without cal-
ciﬁcations (Table 1). This was similar in the separate arteries.
Assessing the mean VWF:Ag level in patients using both calciﬁca-
tion volume, showed the highest levels in patients with both the
highest calciﬁcation volume (Fig. 2). The association between theboth calciﬁcation volume were determined (N ¼ 908)
Any calciﬁcation
N ¼ 652
P value
67.1 (10.7) <0.0001
290 (44.5) 0.014
195 (29.9) 0.677
27.1 (15.6) 0.543
400 (61.3) <0.0001
258 (39.6) <0.0001
104 (16.0) 0.002
303 (46.5) <0.0001
294 (45.1) 0.888
353 (54.1) 0.888
289 (44.3) 0.079
363 (55.7) 0.079
133 (20.4) <0.0001
79 (12.1) 0.741
129 (19.8) 0.963
25 (3.8) <0.0001
286 (43.9) 0.016
hown.
Fig. 2. Relationship between aortic arch and carotid calciﬁcation volume and mean
VWF:Ag levels The relation between aortic arch and carotid calciﬁcation volume
groups and mean VWF:Ag levels (IU/ml).
Fig. 3. Levels of mean VWF:Ag per etiologic subtypes of TIA and ischemic stroke. Mean
and standard error (SE) VWF:Ag levels (IU/ml) in the etiologic subtypes of TIA and
ischemic stroke according to the TOAST criteria. * indicates P < 0.0001; yP < 0.05. LAA
indicates large artery atherosclerosis; CE, cardio embolism; SVO, small vessel occlu-
sion; Other, stroke of other determined etiology; Undetermined, cerebral ischemia of
undetermined etiology.
Fig. 1. Levels of mean VWF:Ag per group of calciﬁcation volume. a. Mean and standard
error (SE) VWF:Ag levels (in IU/ml) in the aortic arch calciﬁcation volume groups
(*P ¼ 0.006 compared with the ﬁrst group; yP < 0.0001 compared with the ﬁrst group).
b. Mean and standard error (SE) VWF:Ag levels (in IU/ml) in the carotid calciﬁcation
volume groups (*P ¼ 0.001 compared with the ﬁrst group; yP < 0.0001 compared with
the ﬁrst group).
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with blood group O and non-O and this was not statistically sig-
niﬁcant different (P for interaction ¼ 0.11).
3.3. Etiologic subtypes of TIA or stroke and levels of VWF:Ag
Levels of VWF:Ag differed signiﬁcantly between etiologic sub-
types of TIA and ischemic stroke (P ¼ 0.006; Fig. 3). Levels of
VWF:Ag were signiﬁcantly increased in patients with a large artery
atherosclerosis of TIA or ischemic stroke, compared with the other
subtypes (1.59 vs. 1.40 IU/ml, P < 0.0001). Patients with a small
vessel occlusion etiology had signiﬁcantly lower levels of VWF:Ag
compared with the other patients (1.34 vs. 1.45 IU/ml, P ¼ 0.009).
Patients with a deﬁnite atherothrombotic stroke using the A-S-
C-O score variant had signiﬁcantly higher VWF:Ag levels (1.58 IU/
ml) compared with patients with a probable atherothrombotic
stroke (1.40 IU/ml; P ¼ 0.001), other cause of stroke (1.24 IU/ml;
P ¼ 0.009) and unknown cause of stroke (1.32 IU/ml; P < 0.0001).
Patients with a deﬁnite lacunar stroke had signiﬁcantly higher
VWF:Ag levels (1.66 IU/ml) compared with probable athero-
thrombotic (P ¼ 0.04), other cause of stroke (P ¼ 0.013) and with
unknown cause of stroke (P ¼ 0.009).VWF levels were signiﬁcantly correlated with the NIHSS score at
admission (R ¼ 0.183, P < 0.0001) and with functional outcome of
the patients, as determined by the modiﬁed Rankin Scale (mRS) at
discharge (R ¼ 0.222, P < 0.0001). Patients with an unfavorable
outcome (mRS > 2) had signiﬁcantly higher VWF:Ag levels
compared with patients with a favorable outcome (mRS  2)
(1.64 IU/ml vs. 1.41 IU/ml, P < 0.0001). However, these patients did
not have a signiﬁcant higher calciﬁcation volume in both the aortic
arch (23.1 vs. 17.0 mm3, P ¼ 0.17) and carotid arteries (6.6 vs.
5.6 mm3, P ¼ 0.45), compared with patients with a favorable
outcome. Patients with a high VWF:Ag level (>1.43 IU/ml) had a
higher risk of an unfavorable outcome comparedwith patients with
a low VWF:Ag level (1.43 IU/ml; OR 1.45, P < 0.0001) and this
difference remained after additionally adjustment for aortic arch
and carotid calciﬁcation volume. However, there was no signiﬁcant
difference in outcome between patients with blood group O and
non-O (OR 0.95, P ¼ 0.40) Table 2.
Table 2
Association between calciﬁcation volume and VWF:Ag levels.
Calciﬁcation
volume (mm3)
Mean VWF:Ag
(IU/ml) model 1
Mean VWF:Ag
(IU/ml) model 2
Aortic arch
0 1.26  0.03 1.36  0.03
0.01e41 1.42  0.04 1.41  0.04
41.01e257.4 1.54  0.04 1.48  0.04
>257.4 1.67  0.04 1.54  0.05
P for trend <0.0001 0.03
Carotid artery
0 1.27  0.03 1.34  0.03
0.01e10.1 1.47  0.04 1.43  0.04
10.11e63.9 1.49  0.05 1.46  0.04
>63.9 1.73  0.05 1.61  0.05
P for trend <0.0001 <0.0001
Mean VWF:Ag levels (mean  SE) per calciﬁcation volume subgroup.
Model 1: univariate.
Model 2: adjusted for age, sex, blood group and cardiovascular risk factors.
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The main result of our study is a strong positive association
between the extent of atherosclerosis, determined by the calciﬁ-
cation volume in both the aortic arch and the carotid arteries, and
VWF:Ag levels in patients with ischemic stroke. In addition, we
observed that levels of VWF were signiﬁcantly higher in patients
with a large artery atherosclerosis type of ischemic stroke
compared to other stroke subtypes.
To the best of our knowledge, our study is the ﬁrst to investigate
the extent of atherosclerosis, using newly developed quantitative
measurements, and VWF levels in patients with TIA or ischemic
stroke. We found similar positive associations in both aortic arch
calciﬁcation volume and carotid calciﬁcation volume with VWF:Ag
levels. Furthermore, patients with the highest score for both the
aortic arch calciﬁcation volume and carotid calciﬁcation volume
had the highest VWF:Ag levels. VWF:Ag levels were strongly
associated with large artery atherosclerosis.
It is still debatedwhether VWF itself plays a pathogenetic role in
atherogenesis. Despite the fact that several animal models indi-
cated that VWF may lead to a reduction of atherosclerosis [27,28],
multiple human studies failed to conﬁrm this observation. In these
studies a similar extent of atherosclerosis in individuals with severe
von Willebrand disease (VWD), characterized by reduced levels of
VWF, was shown compared with controls [29e33].
It is well known that genetic variations, both within the VWF
gene and outside the VWF gene, strongly determine VWF levels
[11,12,34e36]. One of the main genetic determinants of VWF levels
is the ABO blood group, resulting in 25e30% lower levels in in-
dividuals with blood group O compared to non-O [37]. Also in our
study, ischemic stroke patients with blood group O had 30% lower
VWF:Ag levels compared to patients with blood group non-O, but
did not have lower calciﬁcation volumes. This ﬁnding suggests that
VWF levels do not have a major pathogenetic role in atheroscle-
rosis. In addition, it is still debatable whether blood group is a risk
factor for ischemic stroke [38,39]. An earlier study of our group
already showed that, despite the fact that several genetic variations
were strongly associated with VWF levels, the genetic variations
did not inﬂuence the risk of ischemic stroke [11]. This suggests that
VWF levels are merely a marker of atherosclerosis and thereby
determine the previously found association between increased
VWF:Ag levels and risk of stroke, as atherosclerosis is a well known
important risk factor for TIA and ischemic stroke.
Patients with a small vessel occlusion ischemic stroke had lower
levels of VWF:Ag than the other stroke patients. This was compa-
rable with another study, which showed that patients with a small
vessel disease type of stroke, had lower VWF levels compared withthe large vessel disease and cardio embolism group [7]. These lower
VWF levels may be explained by the fact that in these patients
atherosclerosis does not play a major role in the etiology of stroke.
However, the small arterioles of the brain are presumed to be
affected by various vascular risk factors [40]. This may also lead to
endothelial activation, but only to certain subtypes of lacunar in-
farcts [41]. However, lacunar stroke described in the A-S-C-O score
variant was associated with high VWF:Ag levels. This might be
explained by the difference in the number of patients (N ¼ 22 A-S-
C-O score, N ¼ 183 TOAST classiﬁcation) and a difference in deﬁ-
nition. In this study, VWF:Ag levels were associated with stroke
severity, determined by the NIHSS at admission and with poor
outcome, determined by the mRS at discharge. This is in agreement
with one previous study in patients with acute ischemic and
hemorrhagic stroke inwhich high VWF levels were associated with
a poor modiﬁed Rankin score [42]. Recently we showed in the
prospective population-based Rotterdam study that increased VWF
levels are a predictor of stroke [9]. In this study we have shown that
increased VWF levels and not blood group are a predictor of stroke
outcome suggesting that VWF levels could serve as a risk marker of
stroke outcome. Additionally, because levels of VWF are increased
due to presence of atherosclerosis, VWF could also serve as a useful
marker of atherosclerosis and thereby as a risk marker of stroke.
Somemethodological issues have to be addressed. Strengths of our
studyare the large number of ischemic stroke patients of all ages,with
availabilityofwell-documentedclinical information, extensive scoring
(>96%) of MDCT angiography of the aortic arch and the carotid ar-
teries, and the availability of plasma of nearly all consecutive patients.
Furthermore, we determined calciﬁcations of the aortic arch and
carotid arteries using dedicated commercially available software in
which calciﬁcations of the aortic arch and carotid arteries can be
reproducible quantiﬁed in a speciﬁed range. So far only limited data
was available regarding calciﬁcations in the carotid arteries as a
marker of atherosclerosis. In this study, we found a signiﬁcantly
higher prevalence of cardiovascular risk factors in patients with
calciﬁcations in the aortic arch and carotid arteries than in patients
without calciﬁcations. This is in agreement with another study,
which showed an independent relationship between several car-
diovascular risk factors and carotid calciﬁcations and similar risk
factor proﬁles were found in different vessel beds including the
coronary arteries, aortic arch and carotid arteries [17]. Calciﬁcations
in the aortic arch and carotid arteries were associated with the
presence of stroke and luminal stenosis in previous studies
[18,19,43,44]. This all shows that calciﬁcations in the aortic arch and
carotid arteries can be used as a marker of atherosclerosis.
A potential drawback of our study is that calciﬁcations below
the threshold of 600 HU or outside the scan range were not
detected. Another possible limitation concerns the fact that calci-
ﬁcations are one of the components of an atherosclerotic plaque
and a soft atherosclerotic plaque that contains no calciﬁcation is
therefore not detected [43]. However, it has been shown that the
majority (82%) of atherosclerotic plaques contains some calciﬁca-
tions [25] and therefore this would only minimally affect our re-
sults. In addition, time between stroke and blood sampling was
variable. However, there was no signiﬁcant correlation between
VWF levels and time from event till blood sampling. This suggests
that the time of blood drawn did not inﬂuence the levels of VWF.
Furthermore, patients with signiﬁcant comorbidity, very severe
stroke or those who died within 24 h were not included in this
study, resulting in a relatively less severely affected cohort.
5. Conclusion
In conclusion, our study in patients with TIA or ischemic stroke
indicates that the extent of atherosclerosis, determined by
M.A.H. Sonneveld et al. / Atherosclerosis 230 (2013) 210e215 215calciﬁcations in the aortic arch and carotid arteries, is strongly
associated with VWF levels. In addition, highest VWF levels are
found in large vessel disease, whereas the levels are lower in small
vessel disease. Furthermore, our study suggests that VWFmay have
prognostic value in patients with ischemic stroke.
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